uniQure NV disclosed on September 29, 2026, that the pre-specified primary endpoint in its ongoing Phase I/II study of the Huntington's disease gene therapy ifezuntirgene inilparvovec (AMT-130) did not reach statistical significance at the 48-month mark, according to the company's press release and an accompanying Securities and Exchange Commission filing. Among 12 high-dose patients, the composite Unified Huntington's Disease Rating Scale, or cUHDRS, showed a 44 percent slowing of disease progression compared with an updated external control group, but the result carried a p-value of 0.144, above the conventional 0.05 threshold for significance. Shares of the Amsterdam-based company fell sharply after the disclosure; Investing.com reported the stock "cratered 64%" in trading following the update.

The 48-month figures are a secondary readout and were not part of the Biologics License Application uniQure submitted to the Food and Drug Administration earlier in September, which the agency agreed could rest on the 36-month dataset. That earlier analysis, now updated to include 15 high-dose patients, showed an 80 percent slowing on cUHDRS with a nominal p-value of 0.005, and a 67 percent slowing on a separate measure of functional capacity, Total Functional Capacity (TFC), with a nominal p-value of 0.011. The company's chief medical officer, Walid Abi-Saab, said in the release that the therapy continued to show a treatment effect four years after a single administration.

uniQure attributed the 48-month statistical miss to changes in the comparison group, an external, propensity-score-matched cohort drawn from the ENROLL-HD natural history dataset rather than a randomized placebo arm of the same trial. The company said 53 percent of matched controls had dropped out of follow-up by month 48, and that those who remained were progressing more slowly than those who left, a pattern it described as survivor bias that narrowed the apparent gap between treated patients and controls. A post-hoc sensitivity analysis that substituted an earlier version of the control dataset showed a 54 percent slowing on cUHDRS, with a nominal p-value of 0.041, restoring significance under that alternate comparison. TFC remained nominally significant at 48 months regardless of which control set was used, showing a 61 percent slowing with the updated control (nominal p=0.008) and 68 percent with the prior control (nominal p=0.001).

The reaction among analysts has been mixed. Regulators and investors typically discount statistical adjustments made after a result is already known, and the high-dose group had shrunk from 15 patients at 36 months to 12 at 48 months, a size at which a handful of individual trajectories can move a result. uniQure has said the FDA's review of its BLA continues on the basis of the 36-month data, and the company plans to present the fuller 48-month dataset at a future scientific meeting.